Advertisement

Correction

        In the article entitled, “Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy” (Volume 187, pages 2520–2535 of the November 2017 issue of The American Journal of Pathology; DOI: https://doi.org/10.1016/j.ajpath.2017.07.017) the authors have noticed a labeling error in two of the Supplemental Figures. The key for the bar graphs incorrectly reflect Dysf-null vehicle, Dysf-null prednisone, and Dysf-null deflazacort and these labels should read Dysf-null vehicle, Dysf-null weekly, and Dysf-null daily. The two images are being replaced with the updated versions below. The legends for these figures are correct as published and this labeling error does not change the claims or conclusions presented in this manuscript.

        Linked Article

        • Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy
          The American Journal of PathologyVol. 187Issue 11
          • Preview
            The muscular dystrophies are genetically diverse. Shared pathological features among muscular dystrophies include breakdown, or loss of muscle, and accompanying fibrotic replacement. Novel strategies are needed to enhance muscle repair and function and to slow this pathological remodeling. Glucocorticoid steroids, like prednisone, are known to delay loss of ambulation in patients with Duchenne muscular dystrophy but are accompanied by prominent adverse effects. However, less is known about the effects of steroid administration in other types of muscular dystrophies, including limb-girdle muscular dystrophies (LGMDs).
          • Full-Text
          • PDF
          Open Archive